| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
19,740,000 |
| Market
Cap: |
4.41(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,297,425 |
| 52
Week Range: |
$120.4 - $284.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 21.9 |
| Insider 3/6 Months : 22.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
136,370 |
424,685 |
424,685 |
| Total Buy Value |
$0 |
$30,065,193 |
$77,751,391 |
$77,751,391 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
3 |
10 |
10 |
| Total Shares Sold |
276,067 |
293,667 |
293,667 |
363,156 |
| Total Sell Value |
$67,426,178 |
$71,246,652 |
$71,246,652 |
$90,715,080 |
| Total People Sold |
7 |
8 |
8 |
9 |
| Total Sell Transactions |
15 |
23 |
23 |
28 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2020-05-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(44,903) |
72,875 |
|
- |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2020-05-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(367,333) |
81,380 |
|
- |
|
| Craves Fred B |
Director |
– • • |
2020-05-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(412,236) |
72,875 |
|
- |
|
| Craves Fred B |
Director |
– • • |
2019-12-13 |
4 |
S |
$105.47 |
$126,564,000 |
I/I |
(1,200,000) |
88,152 |
|
- |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2019-12-13 |
4 |
S |
$105.47 |
$126,564,000 |
I/I |
(1,200,000) |
88,152 |
|
- |
|
| Lynch Brian Joseph |
SVP and General CounselOfficer |
• – – |
2019-04-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
530 |
|
- |
|
| Milligan David V |
Director |
– • – |
2018-11-21 |
4 |
S |
$112.54 |
$2,250,800 |
D/D |
(20,000) |
0 |
|
- |
|
| Friedman Paul A |
Chief Executive Officer |
• • – |
2018-11-20 |
4 |
B |
$117.88 |
$471,520 |
D/D |
4,000 |
161,128 |
2.81 |
- |
|
| Milligan David V |
Director |
– • – |
2018-11-19 |
4 |
S |
$131.60 |
$1,316,000 |
D/D |
(10,000) |
20,000 |
|
- |
|
| Craves Fred B |
Director |
– • • |
2018-11-19 |
4 |
B |
$123.17 |
$249,387 |
D/D |
2,000 |
298,067 |
3.92 |
- |
|
| Friedman Paul A |
Chief Executive Officer |
• • – |
2018-11-19 |
4 |
B |
$124.00 |
$496,000 |
D/D |
4,000 |
157,128 |
2.81 |
- |
|
| Milligan David V |
Director |
– • – |
2018-11-14 |
4 |
OE |
$16.46 |
$164,600 |
D/D |
10,000 |
30,000 |
|
- |
|
| Milligan David V |
Director |
– • – |
2018-09-18 |
4 |
OE |
$9.45 |
$189,000 |
D/D |
20,000 |
20,000 |
|
- |
|
| Schneebaum Marc R |
Chief Financial Officer |
• – – |
2018-06-11 |
4 |
S |
$287.46 |
$2,903,059 |
D/D |
(10,099) |
41,668 |
|
- |
|
| Schneebaum Marc R |
Chief Financial Officer |
• – – |
2018-06-11 |
4 |
OE |
$61.60 |
$689,409 |
D/D |
7,957 |
51,767 |
|
- |
|
| Craves Fred B |
Director |
– • • |
2018-06-11 |
4 |
S |
$287.46 |
$1,698,314 |
I/I |
(5,908) |
113,472 |
|
- |
|
| Craves Fred B |
Director |
– • • |
2018-06-11 |
4 |
S |
$287.46 |
$78,790,486 |
I/I |
(274,092) |
5,264,382 |
|
- |
|
| Taub Rebecca |
Chief Medical Officer, EVP R&D |
• • – |
2018-06-11 |
4 |
S |
$287.46 |
$21,135,784 |
I/I |
(73,526) |
655,540 |
|
- |
|
| Bay City Capital Fund Llc |
Director |
– • • |
2018-06-11 |
4 |
S |
$287.46 |
$80,488,800 |
I/I |
(280,000) |
113,472 |
|
- |
|
| Friedman Paul A |
Chief Executive Officer |
• • – |
2018-06-11 |
4 |
S |
$287.46 |
$21,135,784 |
I/I |
(73,526) |
655,540 |
|
- |
|
| Levy Richard S |
Director |
– • – |
2017-08-23 |
4 |
B |
$16.08 |
$32,236 |
D/D |
2,000 |
9,100 |
2.39 |
- |
|
| Levy Richard S |
Director |
– • – |
2017-08-22 |
4 |
B |
$15.99 |
$57,209 |
D/D |
3,550 |
7,100 |
2.39 |
- |
|
| Levy Richard S |
Director |
– • – |
2017-08-21 |
4 |
B |
$15.67 |
$56,358 |
D/D |
3,550 |
3,550 |
2.39 |
- |
|
| Taub Rebecca |
Chief Medical Officer, EVP R&D |
• • • |
2016-07-22 |
4/A |
A |
$0.00 |
$0 |
D/D |
30,626 |
434,758 |
|
- |
|
| Schneebaum Marc R |
Chief Financial Officer |
• – – |
2016-07-22 |
4/A |
A |
$0.00 |
$0 |
D/D |
24,501 |
43,809 |
|
- |
|
416 Records found
|
|
Page 5 of 17 |
|
|
6.29 (2.74%) 
